Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT) — IMPROVIT  

Antifungal Prophylaxis of Invasive Fungal Infections Clinical Trial

Official title: Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)

Status Completed

Clinical Trial Summary

Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Antifungal Prophylaxis of Invasive Fungal Infections
• Infection
• Mycoses

• NCT number: NCT00289991
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 3
• Start date: March 2006
• Completion date: February 2009